Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Macarthys Laboratories Limited T/A Martindale Pharma, Bampton Road, Romford, Essex, RM3 8UG, United Kingdom
Hypersensitivity to the active ingredient or to other ingredients of the product.
Sodium Citrate should not be administered to patients with metabolic or respiratory alkalosis, hypocalcaemia, or hypochlorhydria. Sodium containing salts should be administered extremely cautiously to patients with heart failure, oedema, renal impairment, hypertension, or aldosteronism. (During treatment of acidosis, frequent monitoring of serum-electrolyte concentrations and acid-base status is essential. Alkalinisation of the urine by bicarbonates or bicarbonate precursors leads to increased renal clearance of acidic drugs.) However, urinary alkalinisation prolongs the half-life of basic drugs and may result in toxicity.
Citrates and Citric Acid enhance intestinal aluminium absorption in renal patients which may lead to increased, harmful serum aluminium levels. It has therefore been suggested that patients with renal failure taking aluminium compounds to control phosphate absorption should not be prescribed citrate or citric acid containing products.
As with all antacids, sodium citrate may affect the absorption of many drugs.
Use as indicated above.
Not applicable.
There are no further effects other than those mentioned in Sections 4.3, 4.4, 4.5 and 4.9 of the Summary of Product Characteristics.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
